Ignite Creation Date:
2025-12-24 @ 2:40 PM
Ignite Modification Date:
2026-01-22 @ 4:41 PM
Study NCT ID:
NCT02558959
Status:
COMPLETED
Last Update Posted:
2018-02-13
First Post:
2015-09-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Sponsor:
Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2017-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-12-31
Completion Date Type:
ACTUAL
First Submit Date:
2015-09-21
First Submit QC Date:
None
Study First Post Date:
2015-09-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-02-10
Last Update Post Date:
2018-02-13
Last Update Post Date Type:
ACTUAL